Tags

Type your tag names separated by a space and hit enter

Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease.
Ther Apher Dial. 2013 Aug; 17(4):363-7.TA

Abstract

Chronic kidney disease (CKD) is common and several factors affect its progression to end-stage renal disease (ESRD). The main goal of our study was to assess the influence of underlying kidney disease and some other important factors during the time of CKD progression to ESRD. A retrospective study of 91 patients (57 men, 34 women; average age 57.7 ± 13.2 years) was carried out. Patients were monitored at least one month before the first renal replacement treatment (RRT). Estimated glomerular filtration rate (eGFR) at first referral to nephrologist was determined by Modification of Diet in Renal Disease equation. Proteinuria was assessed semiquantitatively with dipsticks. Thirty-five patients (38.5%) had diabetic nephropathy (DN), 21 (23.1%) hypertensive nephrosclerosis (HN), 21 (23.1%) adult polycystic kidney disease (APKD) and 14 (15.4%) immunoglobulin A nephropathy (IgAN). Average eGFR at first referral for DN patients was 20.1, and then 23.4 for HN, 35.5 for APKD, and 36.4 mL/min per 1,73 m(2) for IgAN patients. Average time between first nephrological visit and first RRT was 28.4 months for DN patients, 41 for HN, 80.8 for APKD, and 70.1 for IgAN patients. Comparison of all four groups of CKD patients showed that in patients with APKD and IgAN impairment of kidney function to ESRD had progressed statistically significantly slower (P < 0.001). When eGFR at referral, proteinuria, smoking, and renin-angiontensin-aldosterone blockade treatment had been added into the model, patients with APKD and IgAN had a statistically significant longer period between first nephrological visit and first RRT (P < 0.026). In comparison with patients with other underlying causes of CKD, patients with APKD and IgAN had a statistically significant slower progression rate of CKD to ESRD.

Authors+Show Affiliations

Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Maribor, Slovenia. robert.ekart2@guest.arnes.siNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23931872

Citation

Ekart, Robert, et al. "Chronic Kidney Disease Progression to End Stage Renal Disease: a Single Center Experience of the Role of the Underlying Kidney Disease." Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, vol. 17, no. 4, 2013, pp. 363-7.
Ekart R, Ferjuc A, Furman B, et al. Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease. Ther Apher Dial. 2013;17(4):363-7.
Ekart, R., Ferjuc, A., Furman, B., Gerjevič, Š., Bevc, S., & Hojs, R. (2013). Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease. Therapeutic Apheresis and Dialysis : Official Peer-reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 17(4), 363-7. https://doi.org/10.1111/1744-9987.12079
Ekart R, et al. Chronic Kidney Disease Progression to End Stage Renal Disease: a Single Center Experience of the Role of the Underlying Kidney Disease. Ther Apher Dial. 2013;17(4):363-7. PubMed PMID: 23931872.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chronic kidney disease progression to end stage renal disease: a single center experience of the role of the underlying kidney disease. AU - Ekart,Robert, AU - Ferjuc,Anita, AU - Furman,Barbara, AU - Gerjevič,Špela, AU - Bevc,Sebastjan, AU - Hojs,Radovan, PY - 2013/8/13/entrez PY - 2013/8/13/pubmed PY - 2014/4/29/medline KW - Chronic kidney disease KW - Disease progression KW - End-stage renal disease KW - Glomerular filtration rate SP - 363 EP - 7 JF - Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy JO - Ther Apher Dial VL - 17 IS - 4 N2 - Chronic kidney disease (CKD) is common and several factors affect its progression to end-stage renal disease (ESRD). The main goal of our study was to assess the influence of underlying kidney disease and some other important factors during the time of CKD progression to ESRD. A retrospective study of 91 patients (57 men, 34 women; average age 57.7 ± 13.2 years) was carried out. Patients were monitored at least one month before the first renal replacement treatment (RRT). Estimated glomerular filtration rate (eGFR) at first referral to nephrologist was determined by Modification of Diet in Renal Disease equation. Proteinuria was assessed semiquantitatively with dipsticks. Thirty-five patients (38.5%) had diabetic nephropathy (DN), 21 (23.1%) hypertensive nephrosclerosis (HN), 21 (23.1%) adult polycystic kidney disease (APKD) and 14 (15.4%) immunoglobulin A nephropathy (IgAN). Average eGFR at first referral for DN patients was 20.1, and then 23.4 for HN, 35.5 for APKD, and 36.4 mL/min per 1,73 m(2) for IgAN patients. Average time between first nephrological visit and first RRT was 28.4 months for DN patients, 41 for HN, 80.8 for APKD, and 70.1 for IgAN patients. Comparison of all four groups of CKD patients showed that in patients with APKD and IgAN impairment of kidney function to ESRD had progressed statistically significantly slower (P < 0.001). When eGFR at referral, proteinuria, smoking, and renin-angiontensin-aldosterone blockade treatment had been added into the model, patients with APKD and IgAN had a statistically significant longer period between first nephrological visit and first RRT (P < 0.026). In comparison with patients with other underlying causes of CKD, patients with APKD and IgAN had a statistically significant slower progression rate of CKD to ESRD. SN - 1744-9987 UR - https://www.unboundmedicine.com/medline/citation/23931872/Chronic_kidney_disease_progression_to_end_stage_renal_disease:_a_single_center_experience_of_the_role_of_the_underlying_kidney_disease_ DB - PRIME DP - Unbound Medicine ER -